John Polansky, MD
Ophthalmology · Eugene, ORNPI 1942208640
Payments from drug & device makers
Across 55 payments — averaging $38.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$591
- Alcon$388
- Sun Pharmaceutical Industries Inc.$197
- Bausch & Lomb Americas Inc.$179
- Amgen$154
- Heidelberg Engineering, Inc.$94
- plus $504 from 11 others
What the payments were for
- Food & beverage$2,107100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $591 |
| Alcon | 5 | $388 |
| Sun Pharmaceutical Industries Inc. | 6 | $197 |
| Bausch & Lomb Americas Inc. | 5 | $179 |
| Amgen | 2 | $154 |
| Heidelberg Engineering, Inc. | 1 | $94 |
| Aerie Pharmaceuticals, Inc. | 4 | $90 |
| Oyster Point Pharma, Inc. | 3 | $82 |
| Rxsight Inc | 1 | $69 |
| Sight Sciences, Inc. | 1 | $55 |
| Biotissue Holdings Inc. | 2 | $48 |
| Novartis | 2 | $44 |
| Thea Pharma Inc. | 2 | $34 |
| Kala Pharmaceuticals, Inc. | 2 | $34 |
| Astellas Pharma US Inc | 1 | $18 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
| Ivantis, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$145
- CEQUA$107
- TEPEZZA$106
- Clareon$106
How this compares
$2,107 in reported general payments places this provider in the 70th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 64 | $778 |
| Prednisolone Acetate | 12 | $460 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 33 | $430 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $271 |
| Brimonidine Tartrate | 24 | $253 |
| Timolol Maleate | 14 | $105 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Eugene
- Annette Chang SimsEugene$161K
- Balamurali AmbatiEugene$38K
- Richard HoffmanEugene$17K
- Eric NiespodzonyEugene$10K
- Justin EtzelEugene$6K
- Jason GrossEugene$6K
- John HainesEugene$6K
- Joseph MandoEugene$4K
- Shelley JelineoEugene$4K
- Robert BeardsleyEugene$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.